Gusto Giusto

Gusto Global is a biotechnology company focused on the development of live biotherapeutic products (LBPs) derived from the human microbiome. Utilizing its proprietary GUSTO (Genomic Understanding of Systems Taxonomy and Outcomes) platform, the company designs defined bacterial consortia to modulate the immune system and treat complex diseases. Gusto Global's primary focus areas include inflammatory bowel disease (IBD) and immuno-oncology, where it aims to restore healthy microbial function. The company has established a significant strategic partnership with Takeda Pharmaceutical Company to discover and develop novel microbiome-based therapies.